MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation |
|
|
| Recruiting | 3 | 1594 | Europe, Canada, US, RoW | Teclistamab, JNJ-64007957, Lenalidomide | Stichting European Myeloma Network, Janssen Pharmaceutica | Multiple Myeloma | 04/28 | 04/32 | | |
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 3 | 750 | Europe, Canada, Japan, US, RoW | Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine | Stichting European Myeloma Network, Janssen Research & Development, LLC | Multiple Myeloma | 06/33 | 08/40 | | |
